Literature DB >> 34633467

Garcinol blocks motor behavioural deficits by providing dopaminergic neuroprotection in MPTP mouse model of Parkinson's disease: involvement of anti-inflammatory response.

Banashree Chetia Phukan1, Ankumoni Dutta1,2, Satarupa Deb1, Rubul Saikia1, Muhammed Khairujjaman Mazumder3, Rajib Paul4, Pallab Bhattacharya5, Rajat Sandhir6, Anupom Borah7.   

Abstract

Although the etiology of Parkinson's disease (PD) is poorly understood, studies in animal models revealed loss of dopamine and the dopaminergic neurons harbouring the neurotransmitter to be the principal cause behind this neuro-motor disorder. Neuroinflammation with glial cell activation is suggested to play a significant role in dopaminergic neurodegeneration. Several biomolecules have been reported to confer dopaminergic neuroprotection in different animal models of PD, owing to their anti-inflammatory potentials. Garcinol is a tri-isoprenylated benzophenone isolated from Garcinia sp. and accumulating evidences suggest that this molecule could provide neuroprotection by modulating oxidative stress and inflammation. However, direct evidence of dopaminergic neuroprotection by garcinol in the pre-clinical model of PD is not yet reported. The present study aims to investigate whether administration of garcinol in the MPTP mouse model of PD may ameliorate the cardinal motor behavioural deficits and prevent the loss of dopaminergic neurons. As expected, garcinol blocked the parkinsonian motor behavioural deficits which include akinesia, catalepsy, and rearing anomalies in the mice model. Most importantly, the degeneration of dopaminergic cell bodies in the substantia nigra region was significantly prevented by garcinol. Furthermore, garcinol reduced the inflammatory marker, glial fibrillary acidic protein, in the substantia nigra region. Since glial hyperactivation-mediated inflammation is inevitably associated with the loss of dopaminergic neurons, our study suggests the anti-inflammatory role of garcinol in facilitating dopaminergic neuroprotection in PD mice. Hence, in the light of the present study, it is suggested that garcinol is an effective anti-parkinsonian agent to block motor behavioural deficits and dopaminergic neurodegeneration in PD.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Dopaminergic neurons; Garcinol; Inflammation; Motor behaviour; Neuroprotection; Substantia nigra

Mesh:

Substances:

Year:  2021        PMID: 34633467     DOI: 10.1007/s00221-021-06237-y

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  46 in total

1.  Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression.

Authors:  Karanam Balasubramanyam; M Altaf; Radhika A Varier; V Swaminathan; Aarti Ravindran; Parag P Sadhale; Tapas K Kundu
Journal:  J Biol Chem       Date:  2004-05-19       Impact factor: 5.157

2.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.

Authors:  Francesco Fornai; Oliver M Schlüter; Paola Lenzi; Marco Gesi; Riccardo Ruffoli; Michela Ferrucci; Gloria Lazzeri; Carla L Busceti; Fabrizio Pontarelli; Giuseppe Battaglia; Antonio Pellegrini; Ferdinando Nicoletti; Stefano Ruggieri; Antonio Paparelli; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

3.  Oxidative stress and mitochondrial dysfunction are the underlying events of dopaminergic neurodegeneration in homocysteine rat model of Parkinson's disease.

Authors:  Nivedita Bhattacharjee; Anupom Borah
Journal:  Neurochem Int       Date:  2016-10-11       Impact factor: 3.921

Review 4.  Microglia-mediated neurotoxicity: uncovering the molecular mechanisms.

Authors:  Michelle L Block; Luigi Zecca; Jau-Shyong Hong
Journal:  Nat Rev Neurosci       Date:  2007-01       Impact factor: 34.870

Review 5.  Garcinol, a multifaceted sword for the treatment of Parkinson's disease.

Authors:  Satarupa Deb; Banashree Chetia Phukan; Muhammed Khairujjaman Mazumder; Ankumoni Dutta; Rajib Paul; Pallab Bhattacharya; Rajat Sandhir; Anupom Borah
Journal:  Neurochem Int       Date:  2019-04-12       Impact factor: 3.921

6.  Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.

Authors:  Reena Haobam; Kizhakke M Sindhu; Goutam Chandra; Kochupurackal P Mohanakumar
Journal:  Behav Brain Res       Date:  2005-09-08       Impact factor: 3.332

7.  A highly reproducible rotenone model of Parkinson's disease.

Authors:  Jason R Cannon; Victor Tapias; Hye Mee Na; Anthony S Honick; Robert E Drolet; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2009-05       Impact factor: 5.996

Review 8.  Neuroinflammation: the devil is in the details.

Authors:  Damon J DiSabato; Ning Quan; Jonathan P Godbout
Journal:  J Neurochem       Date:  2016-05-04       Impact factor: 5.372

9.  The successive alleys test of anxiety in mice and rats.

Authors:  Robert M J Deacon
Journal:  J Vis Exp       Date:  2013-06-17       Impact factor: 1.355

10.  Garcinol Upregulates GABAA and GAD65 Expression, Modulates BDNF-TrkB Pathway to Reduce Seizures in Pentylenetetrazole (PTZ)-Induced Epilepsy.

Authors:  Fang Hao; Li-Hua Jia; Xiao-Wan Li; Ying-Rui Zhang; Xue-Wu Liu
Journal:  Med Sci Monit       Date:  2016-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.